new glp retatrutide 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Phase 2 Trial of Retatrutide

Capturing the Opportunity: The convergence of the booming GLP-1 market and the growing demand for behavior change solutions creates a once-in-a-lifetime business opportunity for digital health companies that offer behavioral change support

Semaglutide mimics the action of the naturally occurring hormone GLP-1, which is involved in the regulation of blood sugar levels and appetite

The aim of this retrospective study is to report and analyze the results of the use of arGLP-1 in patients experiencing insufficient weight loss or weight regain after bariatric surgery

Source data Source Data Fig

You must be logged in to post a review.

and have not been demonstrated to the FDA to be safe or effective for their intended use